Guardant Health, Inc.

Guardant Health, Inc. (NASDAQ: GH) is a leading precision oncology company focused on transforming patient care through advanced blood and tissue-based testing, real-world data analytics, and artificial intelligence. The company's website is www.guardanthealth.com.

Guardant Health operates across three primary business segments: therapy selection, minimal residual disease detection and recurrence monitoring, and early cancer screening. The therapy selection segment includes the Guardant360 CDx test, the first FDA-approved comprehensive liquid biopsy for tumor mutation profiling and companion diagnostic applications across non-small cell lung cancer, colorectal cancer, and breast cancer. The company also offers the Guardant360 Liquid test measuring over 740 genes and the Guardant360 Tissue test incorporating comprehensive multiomics analysis. The minimal residual disease segment features the Guardant Reveal test for detecting residual and recurring disease in early-stage cancer patients and monitoring therapy response in advanced-stage patients. The screening segment centers on the Shield blood test, the first FDA-approved blood test for primary colorectal cancer screening that meets Medicare coverage requirements.

Beyond clinical diagnostics, Guardant Health serves biopharmaceutical companies through its GuardantINFINITY and GuardantOMNI tests for clinical research and therapy development, along with the GuardantINFORM platform providing genomic and epigenetic insights into disease progression and treatment impact. The company's proprietary Smart Platform leverages genomic, epigenomic, and RNA-based data to deliver multiomic insights scalable from research to clinical applications.

Guardant Health operates clinical laboratories in Redwood City and Palo Alto, California, and Long Island City, New York, with research and development centers across multiple California locations. The company maintains a targeted sales organization focused on oncologists, cancer centers, and primary care physicians in the United States, while expanding internationally through partnerships with cancer centers, research organizations, and laboratory companies in Europe, Asia, the Middle East, and Africa. The company has established partnerships with leading institutions including Vall D'Hebron Institute of Oncology in Spain, The Royal Marsden NHS Foundation Trust in the United Kingdom, Policlinico Gemelli in Italy, and Adicon Holdings in China to advance global commercialization of its testing platform.